Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07310836) titled 'A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver Transplantation' on Dec. 16, 2025.
Study Type: Observational
Primary Sponsor: Ningbo Medical Center Lihuili Hospital
Condition:
Hepatocellular Carcinoma
Liver Transplantation
Intervention:
Combination Product: Locoregional Therapy (LRT) + Systemic Drug Therapy
Recruitment Status: Not recruiting
Date of First Enrollment: December 20, 2025
Target Sample Size: 300
To kno...